Growth hormone in inflammatory bowel disease.

Area of Science:

• Gastroenterology
• Endocrinology
• Immunology

Background:

• Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, involves chronic inflammation and catabolism.
• The growth hormone/insulin-like growth factor-I axis plays a crucial role in IBD by influencing epithelial cell kinetics, collagen deposition, and immunomodulation.
• Growth hormone has demonstrated therapeutic potential in IBD, but acquired resistance is a significant challenge.

Purpose of the Study:

• To investigate the mechanisms of acquired growth hormone resistance in IBD.
• To explore the role of proinflammatory cytokines, such as TNF-alpha and interleukin-6, in mediating this resistance.
• To evaluate the potential of anti-TNF-alpha therapy to reverse growth hormone resistance in IBD.

Main Methods:

• Review of existing clinical and in vivo data on growth hormone axis in IBD.
• Analysis of the impact of proinflammatory cytokines on growth hormone resistance.
• Assessment of infliximab's effect on cytokine levels and growth hormone resistance.

Main Results:

• Acquired growth hormone resistance in IBD is associated with undernutrition and active inflammation.
• Proinflammatory cytokines, particularly TNF-alpha and interleukin-6, are implicated as mediators of growth hormone resistance.
• Anti-TNF-alpha therapy, such as infliximab, effectively reduces cytokine levels and has shown potential to reverse growth hormone resistance in vivo.

Conclusions:

• Growth hormone resistance in IBD is a complex issue influenced by inflammation and nutritional status.
• Targeting TNF-alpha with monoclonal antibodies represents a promising strategy to overcome growth hormone resistance in IBD patients.
• Further research into anti-TNF-alpha therapy could lead to improved treatment outcomes for inflammatory bowel disease.